MENU
ZNTL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Zentalis Pharmaceuticals (ZNTL) Ownership - Who owns Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more
Profile
Industry
N/A
Address
1359 Broadway
Phone
+1 212 433-3791
Employees
168
Web
https://www.zentalis.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
92.64M
P/E Ratio
N/A
Total Cash
391.25M
Projected Growth
N/A
Total Debt
40.46M
Revenue
40.56M
Risk (Beta)
1.46
Dividend Yield
N/A
Total Cash/Share
5.45
Total Debt/Equity
N/A
Revenue/Share
0.95 USD as % of share price
Fundamentals
ZNTL
Capitalization
92.6M
P/E Ratio
N/A
Risk (Beta)
1.46
Dividend Yield
N/A
Total Cash
391M
Total Cash/Share
5.45
Total Debt
40.5M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.95%
Revenue
40.6M
ROE
N/A
Book Value
354M
P/B Ratio
0.27
Cash Flow
N/A
Earnings
-2.5
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
71K
Current Ratio
7.29
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-207.96M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-34.60
Shares Held By Institutions
262M
Shares Outstanding - Current
71.8M
Total Liabilities
96.3M
Total Volume MTD
N/A
Value
1
Gain YTD
-57.426
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
1359 Broadway
Phone
+1 212 433-3791
Employees
168
Web
https://www.zentalis.com